Français Néerlandais Japonais Chinois Allemand Espagnol Portugais

Lille’s Macopharma uses cell therapy to fight diabetes

07 Apr 2015 | Health Nutrition, A region on the move

Lille-based Macopharma, a major specialist player in pharmaceuticals, has developed an automated culturing system to optimize preservation of pancreatic islets—cells that play a key role in treating diabetes.

Macopharma innovation - Health- Lille Region

Prisma—a pioneer in diabetes therapy

Macopharma’s revolutionary Prisma (Pancreatic Islet System Automate unit) breaks new ground in biotherapy.  The product of four years of R&D, this new machine automatically preserves pancreatic islets, the insulin-secreting cells that are used to treat patients with type 1 diabetes.

Patented technology, bold commercial roll-out

Prisma uses three patented systems: a disposable medical device, a cell chamber that preserves the islets, and a specially optimized cell culture medium. “We’ve already deployed Prisma at three major cell therapy centers,” says Bruno Delorme, head of Biotherapy R&D at Macopharma. “These are Lille’s University Hospital Center (CHRU), our co-developer, plus units in Switzerland and in Sweden.

 

 

Source: Les Echos, Nicole Buyse

 

 

Back to news

News

Durisotti, confidence regained

One year on, what benefit has Durisotti derived from its takeover by the British GFG Alliance? And what effect has Covid had on the newly acquired company?

Obesity: Lille’s University Hospital (CHU) becomes a European pilot site

With state of the art technology, Lille’s CHU is experimenting with a new procedure in the fight against obesity: the B-Clamp. The first of its kind in Europe.

All news